Young-onset epithelioid type malignant peritoneal mesothelioma with loss of BAP1 gene expression

被引:0
作者
Maharaj, Tobias [1 ]
Steele, Chris [2 ]
Gyorffy, Hajnalka [3 ]
Nicholson, Siobhan [4 ]
Milewski, Lukasz [5 ]
Aird, John J. [6 ]
Mulsow, Jurgen [7 ]
Cowzer, Darren [8 ]
机构
[1] Mater Misericordiae Univ Hosp, Gastroenterol, Dublin, Ireland
[2] Letterkenny Univ Hosp, Gastroenterol, Letterkenny, Ireland
[3] Letterkenny Univ Hosp, Histopathol, Letterkenny, Ireland
[4] St James Hosp, Histopathol, Dublin, Ireland
[5] Letterkenny Univ Hosp, Med Oncol, Letterkenny, Ireland
[6] Mater Misericordiae Univ Hosp, Histopathol, Dublin, Ireland
[7] Mater Misericordiae Univ Hosp, Natl Ctr Peritoneal Malignancy, Dublin, Ireland
[8] Mater Misericordiae Univ Hosp, Med Oncol, Dublin, Ireland
关键词
Chemotherapy; Immune Checkpoint Inhibitors; Immunohistochemistry; Oncology; Surgical oncology; PLEURAL MESOTHELIOMA; SYSTEMIC CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; OPEN-LABEL; PHASE-III; COMBINATION; DIAGNOSIS; SURVIVAL; MULTICENTER; CISPLATIN;
D O I
10.1136/bcr-2025-264825
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Malignant peritoneal mesothelioma (MPeM) is a rare malignancy involving the abdominal peritoneum typically presenting after middle age with little known of survival in the young. We present a patient in his 20's with no known asbestos exposure diagnosed with epithelioid-type MPeM and loss of BAP1 gene expression. Our patient demonstrated diffuse unresectable disease at presentation. He had a poor response to first-line treatment carboplatin-pemetrexed chemotherapy followed by ipilimumab plus nivolumab immunotherapy in the second line and carboplatin plus gemcitabine in the third line. Our patient subsequently died 10 months after diagnosis. Despite our patient having favourable prognostic markers such as BAP1 loss in epithelioid subtype mesothelioma, our patient had poor treatment response and survival, highlighting the heterogeneity within this subgroup and likely alternative underlying factors impacting outcomes.
引用
收藏
页数:7
相关论文
共 45 条
[1]   Immunotherapy in malignant peritoneal mesothelioma (Review) [J].
Alaklabi, Sabah ;
Roy, Arya Mariam ;
Skitzki, Joseph J. ;
Iyer, Renuka .
MOLECULAR AND CLINICAL ONCOLOGY, 2023, 18 (04)
[2]  
[Anonymous], 2001, Registries enoc. eurocim version 4.0. european incidence database v2. 3, 730 entity dictionary
[3]   Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma [J].
Arulananda, Surein ;
Thapa, Bibhusal ;
Walkiewicz, Marzena ;
Zapparoli, Giada V. ;
Williams, David S. ;
Dobrovic, Alexander ;
John, Thomas .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :1588-1594
[4]   First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial [J].
Baas, Paul ;
Scherpereel, Arnaud ;
Nowak, Anna K. ;
Fujimoto, Nobukazu ;
Peters, Solange ;
Tsao, Anne S. ;
Mansfield, Aaron S. ;
Popat, Sanjay ;
Jahan, Thierry ;
Antonia, Scott ;
Oulkhouir, Youssef ;
Bautista, Yolanda ;
Cornelissen, Robin ;
Greillier, Laurent ;
Grossi, Francesco ;
Kowalski, Dariusz ;
Rodriguez-Cid, Jeronimo ;
Aanur, Praveen ;
Oukessou, Abderrahim ;
Baudelet, Christine ;
Zalcman, Gerard .
LANCET, 2021, 397 (10272) :375-386
[5]   Prognostic value of high serum levels of CA-125 in malignant secretory peritoneal mesotheliomas affecting young women. A case report with differential diagnosis and review of the literature [J].
Bercero, EA ;
Perez, GMGRY ;
Bragado, FG ;
Jimenez, C .
HISTOPATHOLOGY, 1997, 31 (03) :267-273
[6]   Epidemiology of peritoneal mesothelioma: a review [J].
Boffetta, P. .
ANNALS OF ONCOLOGY, 2007, 18 (06) :985-990
[7]   Malignant peritoneal mesothelioma: a review [J].
Broeckx, Glenn ;
Pauwels, Patrick .
TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (05) :537-542
[8]   Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States [J].
Calthorpe, Lucia ;
Romero-Hernandez, Fernanda ;
Miller, Phoebe ;
Conroy, Patricia C. ;
Hirose, Kenzo ;
Kim, Alex ;
Kirkwood, Kimberly ;
Nakakura, Eric ;
Corvera, Carlos ;
Maker, Ajay V. ;
Alseidi, Adnan ;
Adam, Mohamed Abdelgadir .
CANCERS, 2023, 15 (01)
[9]   Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent [J].
Carteni, G. ;
Manegold, C. ;
Martin Garcia, G. ;
Siena, S. ;
Zielinski, C. C. ;
Amadori, D. ;
Liu, Y. ;
Blatter, J. ;
Visseren-Grul, C. ;
Stahel, R. .
LUNG CANCER, 2009, 64 (02) :211-218
[10]   Impact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC [J].
Chatterjee, Ambarish ;
Kusamura, Shigeki ;
Baratti, Dario ;
Guaglio, Marcello ;
Battaglia, Luigi ;
Deraco, Marcello .
ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) :556-566